A review of the pharmacokinetic and pharmacological properties of a once‐yearly administered histrelin acetate implant in the treatment of prostate cancer

P. Schlegel
DOI: https://doi.org/10.1111/j.1464-410X.2009.08383.x
2009-03-01
BJU International
Abstract:Prostate cancer is one of the most common neoplasms in men, accounting for ≈ 11% of male cancers in Europe [1] with 75% of cases occurring in those aged > 65 years [2]. There are an estimated 200 000 new diagnoses each year in the European Union (EU) where the prostate cancer mortality rate approximates 10% of all cancer deaths among men [3]. When considering trends in cancer mortality in the EU during the 10-year period up to 2000, although the rate declined in some EU countries (Austria, France, Germany, Italy, Luxembourg and the UK), there was generally a 5% increase in other member states [4].
What problem does this paper attempt to address?